Details for Patent: 10,357,616

Which drugs does patent 10,357,616 protect, and when does it expire?

Patent 10,357,616 protects OZEMPIC and is included in one NDA.

This patent has fifteen patent family members in eleven countries.

Summary for Patent: 10,357,616

Title:	Injection device with an end of dose feedback mechanism
Abstract:	The injection device is suitable for injecting insulin.
Inventor(s):	Claus Schmidt Moller, Bo Radmer, Lars Ulrik Nielsen, Christian Peter Enggaard
Assignee:	Novo Nordisk AS
Application Number:	US15/815,976
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,357,616
Patent Claim Types: see list of patent claims	Use; Delivery; Device;

Drugs Protected by US Patent 10,357,616

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-001	Dec 5, 2017		DISCN	Yes	No			Y		Y
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-004	Oct 6, 2022		RX	Yes	Yes			Y		Y
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-002	Apr 9, 2019		RX	Yes	Yes			Y		Y
Novo	OZEMPIC	semaglutide	SOLUTION;SUBCUTANEOUS	209637-003	Mar 28, 2022		RX	Yes	Yes			Y		Y

Foreign Priority and PCT Information for Patent: 10,357,616

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	05075187	Jan 25, 2005

International Family Members for US Patent 10,357,616

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006208606
Brazil	PI0607012
Canada	2595323
China	101107032
Denmark	1877119
European Patent Office	1877119
Spain	2689536